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Abstract
Objectives. Identifying blood-based biomarkers that predict treatment response in RA is a clinical priority. We inves-
tigated differential DNA methylation as a candidate biomarker of response for the first-line drug used in RA, MTX.
Methods. DNA methylation was measured in DNA samples from individuals recruited to the Rheumatoid Arthritis
Medication Study. Differentially methylated positions were compared between whole blood samples collected at base-
line and at 4 weeks from patients who, by 6 months, had a good (n= 34) or poor response (n= 34) to MTX using linear
modelling, adjusting for gender, age, cell composition, baseline 28-joint disease activity score (DAS28) and smoking
status. Analyses also compared methylation with changes in DAS28 and changes in swollen joint count and tender joint
count, and changes in CRP over the initial 6 months after MTX commencement. Differentially methylated positions
showing significant differences with any response parameter were tested using pyrosequencing in an independent
group of 100 patients from the Rheumatoid Arthritis Medication Study.
Results. In the discovery group, two CpG sites showed methylation changes at 4 weeks associated with clinical EULAR
response by 6 months. Significant changes in methylation for three differentially methylated positions associated with
change in tender joint counts, three with change in swollen joint count and a further four with change in CRP. Of the 12
CpGs, four showed replicated association in an independent dataset of samples from the Rheumatoid Arthritis
Medication Study.
Conclusion. These data represent an advance on current practice by contributing to a personalized medicine strategy
allowing an escalation or change in therapy as early as 4 weeks.
Key words: rheumatoid arthritis, treatment response, methotrexate, pharmacogenetics, DNA methylation, epi-
genetics, DMARD
Rheumatology key messages
. Up to 40% of rheumatoid arthritis patients do not respond adequately to methotrexate treatment.
. Four CpGs measured after 4 weeks of treatment correlated with improvement in disease activity.
. Integrating CpGs with other early biomarkers may predict improvement in disease activity at 6 months.
Introduction
Multiple studies have shown that patients with RA who
receive prompt and efficacious treatment resulting in sus-
tained remission are less likely to experience long-term
disability and premature mortality [13]. The first choice
conventional synthetic disease-modifying antirheumatic
drug (csDMARD) treatment for RA is MTX; however, up
to 40% of patients do not respond adequately to treat-
ment after 2 years [4]. A clinical decision regarding re-
sponse to MTX is generally made at 6 months following
treatment initiation. During that time, prolonged inflamma-
tion can cause lasting disability in patients who are non-
responsive to treatment. Therefore, it is imperative to
identify earlier biomarkers of response so that patients
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can be placed on a more effective personalized treatment
regimen earlier in their disease course.
One possible biomarker of MTX response is DNA
methylation, in which a methyl group is added to a cyto-
sineguanine (CG) dinucleotide (CpG). Approximately
7080% of all CpGs across the genome are methylated
[5] and typically cluster in gene promoter regions, known
as CpG islands, which are usually hypomethylated in tran-
scriptionally active genes [6]. There is increasing evidence
for a role of DNA methylation in susceptibility to RA. For
example, the largest epigenome-wide association study
(EWAS) for RA susceptibility to date compared DNA
methylation at 485 000 CpG sites in 354 RA cases and
337 healthy controls and reported 10 differentially methy-
lated CpG sites within the MHC region at known RA gen-
etic risk loci [7]. The authors suggested that some genetic
associations at the MHC region may be mediated by DNA
methylation by affecting gene regulation or alternative
splicing [7].
DNA methylation is also a candidate biomarker for
treatment response. For example, one study compared
DNA methylation signatures in whole blood from 36
good and 36 poor responders to etanercept, and two dif-
ferentially methylated positions (DMPs) mapping to the
LRPAP1 gene were identified [8]. Methylation levels of
these DMPs were also associated with genotype of the
rs3468 variant in LRPAP1 and the genetic association with
response was replicated in an independent set of anti-
TNF-treated subjects (n= 1204). Another study investi-
gated DNA methylation in CD4+ T cells from JIA patients;
145 DMPs were identified between cases and controls
(false discovery rate adjusted P< 0.1), but just 11 DMPs
remained associated when four MTX-treated individuals
were removed, suggesting a possible role of MTX on
DNA methylation in CD4+ T cells in JIA cases [9].
However, no previous studies have investigated DNA
methylation as a biomarker of future response to MTX.
We, therefore, performed an EWAS to identify DMPs
between good and poor responders at 6 months after initi-
ating MTX treatment for the first time in patients with RA,
both at baseline and following 4 weeks of therapy, in order
to identify a very early biomarker of response. Using
genome-wide genetic data, we further investigated the
correlation of differential methylation with genotype to
identify whether methylation quantitative trait loci
(meQTLs) were present and could potentially act as a sur-
rogate marker.
Methods
Patient selection
The Rheumatoid Arthritis Medication Study (RAMS) is a
UK multicentre 1 year observational study of patients
diagnosed with RA or inflammatory polyarthritis who com-
mence MTX for the first time. Whole blood samples were
collected pre-treatment (baseline) and 4 weeks following
therapy. Sera were extracted from the whole blood sam-
ples and measured for CRP levels. DNA was extracted
from whole blood samples collected at baseline and
from samples collected following 4 weeks of MTX therapy.
Clinical information was collected at baseline and
6 months thereafter, including 28 swollen joint count
(SJC) and tender joint count (TJC). Using data for CRP,
SJC, TJC and GH (patient global health; patient reported
global health assessment ranging from 0 mm = best and
100 mm = worst), the patients’ 28-joint disease activity
score (DAS28) was calculated at baseline and 6 months.
Response to MTX was determined at 6 months using the
EULAR criteria for response where good response was
defined as having DAS28 43.2 and >1.2 improvement
of DAS28 at 6 months, and poor response was defined
as having DAS28 >5.1 and 40.6 improvement of
DAS28 at 6 months [10]. Patients who had improved the
most by 6 months were selected as good responders, and
patients whose DAS28 showed the least improvement (or
worsened) by 6 months were selected as poor responders
for the genome-wide methylation analysis. Baseline char-
acteristics of the patients selected for the genome-wide
methylation analyses are found in Table 1. RAMS was
approved by the Central Manchester NHS Research
Ethics Committee (ref. 08/H1008/25) and all patients pro-
vided written consent.
Epigenome-wide methylation analysis
Five hundred nanograms of DNA was bisulphite converted
using an optimized protocol of the manufacturer (Zymo
Research, Irvine, CA, USA). Epigenome-wide methylation
was measured using HumanMethylation450 BeadChips
according to the manufacturer’s protocol (Illumina, San
Diego, CA, USA).
All statistical analyses were performed in R 3.2.0
(R Foundation for Statistical Computing, Vienna, Austria).
Using previously validated methodology, linear models
TABLE 1 Baseline patient characteristics in the RAMS
cohort
Good
responders
(n=34)
Poor
responders
(n=34)
Female, n (%) 26 (76.5) 28 (82.3)
Age at baseline, mean (S.D.),
years
58.8 (14.5) 58.3 (14.2)
Baseline DAS28, mean (S.D.) 4.9 (1.0) 4.3 (1.4)
Swollen joint count, median
(IQR)
6.5 (120) 4.5 (018)
Tender joint count, median
(IQR)
9.5 (425) 9 (027)
CRP, median (IQR), mg/ml 7.5 (176) 3.5 (028)
Smoking status at baseline, n (%)
Never smoked 17 (50) 15 (44.)
Current smoker 6 (17.6) 9 (26.4)
Ex-smoker 11 (32.4) 10 (29.4)
Clinical and demographic data were collected at baseline
(pre-treatment) and at 6 months following treatment. Results
are presented as mean (S.D.) or median (IQR) if data are
skewed. IQR: interquartile range.
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created using the limma package were used to test for
association between CpG methylation and treatment re-
sponse in pre-treatment samples and in those taken at
4 weeks, as well as differential methylation between the
two time points in both the good and the poor responder
groups, separately [8, 11]. The changes in DAS28 score
and its components (SJC, TJC, CRP) were compared with
changes in methylation at baseline and 4 weeks separ-
ately, and with changes between baseline and 4 weeks
for each responder group. By looking for these changes
in the individual responder groups improved the power to
detect smaller changes in methylation, which associate
with the DAS28 and its components in a more extreme
phenotype The GH component of the DAS was not
included in these analyses as it is a very subjective vari-
able and does not always correlate with other objective
measures of RA disease activity [12]. The baseline DAS28
score, sex and age were included as covariates in the
model as well as cell type composition using the validated
Houseman method [13], and smoking status (never
smoked, past smoker, current smoker) since whole
blood is a heterogeneous group of cell types with each
cell type having its own distinct methylation profile, and
also smoking is also known to influence global DNA
methylation [1316]. P-values were adjusted using the
Benjamini and Hochberg method to control the false dis-
covery rate [11]. Power to detect differential DNA methy-
lation between responder groups was estimated using
established analytical techniques, and DMPs with an un-
adjusted P-value <1 106 (arbitrary threshold) was
deemed as a suggestive association and prioritized for
replication [17].
Replication using pyrosequencing
An independent replication cohort for pyrosequencing was
selected from RAMS. This cohort included 28 extremely
good and 35 extremely poor responders using the same
EULAR definitions as in the discovery cohort, as well 36
intermediate responders. Intermediate response was deter-
mined using the EULAR criteria where patients had an im-
provement of DAS28 at 6 months >0.6 and 41.2 with a
present DAS2843.2 or >3.2 and45.1, or an improvement
at 6 months by >1.2 with present DAS28 >3.2 and45.1, or
>5.1 [10]. All patients had DNA samples taken at baseline
(pre-treatment) and following 4 weeks of treatment with MTX.
Pyrosequencing assays were designed or selected to
target DMPs with evidence for association from the array-
based genome-wide analysis (Qiagen, Hilden, Germany).
For each assay, 10 ng of bisulphite-converted DNA was
amplified by PCR as suggested by the manufacturer
(Qiagen). The PCR product (1020ml) was bound to
streptavidinSepharose High Performance Beads (GE
Healthcare, Chalfont St. Giles, UK), and washed with
70% ethanol, PyroMark denaturation solution, and
PyroMark wash buffer (Qiagen) before being added to
0.3mM sequencing primer diluted to 25ml in annealing
buffer (Qiagen). The solution was heated to 80C for
2 min to allow the biotin-labelled DNA strand to anneal to
the primers, and then cooled to room temperature before
being loaded into the pyrosequencer, PyroMark Q24
(Qiagen). The percentage methylation value at each CpG
site was compared with the b-values for that site derived
from the epigenome wide analysis. Statistical analysis
using a linear regression model for comparisons between
time point, response status and change in DAS28 compo-
nent at each time point and within responder groups for
baseline and 4 weeks samples separately were repeated to
determine whether an association was replicated in the
same direction and was statistically significant (P-value
<0.05).
Pathway analysis
To gain a better understanding of the biological function of
these replicated methylation changes, pathway analysis
was performed using the epigenome-wide data. For any
CpG site that was replicated in the pyrosequencing ana-
lyses, the top 1000 CpGs in the epigenome-wide results
for its specific comparison (e.g. change in SJC with base-
line samples) were investigated for potential biological
pathways inferred by Gene Ontology using the
missMethyl package in R [18]. A P-value cut-off <105
was used to determine statistical significance of the bio-
logical pathways identified.
meQTL analysis
The DNA samples from the patients in this study were also
genotyped using the Illumina HumanCoreExome-24-v1-0
according to the manufacturer’s protocol (Illumina). The
raw genotype data were assessed using GenomeStudio,
where samples <90% call rate were excluded and the
data was clustered. Data were exported to PLINK v1.07
[19] where variants and individuals with <98% call rate
were excluded. Each chromosome was aligned to The
1000 Genomes Project Phase 3 reference panel using
shapeit.v2.r837 [20]. The imputation was performed
using impute2_2.3.2. From the imputed dataset, whole
chromosomal regions pertaining to the replicated CpG re-
gions were extracted using PLINK v1.07. Using the methy-
lation values from the epigenome-wide data and the
corresponding genome-wide single nucleotide poly-
morphism (SNP) data, SNPs mapped to within 1 million
bases around the replicated CpGs were investigated for
cis-acting meQTLs using the R package, matrixEQTL [21].
Results
Cohort characteristics
Baseline characteristics of the 34 good responders and 34
poor responders to MTX tested in the genome-wide array-
based study are shown in Table 1. No significant differ-
ences were observed between treatment response
groups except for baseline DAS28 score, which was
higher in the good responder group compared with the
poor responder group, and was subsequently added as
a covariate in all analyses. This study had 80% power to
detect a mean methylation difference of 7% between
good responders and poor responders at the 5% signifi-
cance threshold.
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Discovery epigenome-wide association results
A total of 422 557 probes were available for further ana-
lyses in 34 poor responders and 34 good responders at
both time points, where response was determined using
the EULAR criteria at 6 months. The linear regression in
limma identified two DMPs in DNA samples taken at the
4-week time point, which differed between good and poor
responders (P< 1 106). There was no differential
methylation observed between good and poor responders
in the baseline DNA samples, or between time points in
either the good responder group or the poor responder
group. Correlations between methylation changes be-
tween baseline and 4 weeks and changes in the individual
DAS28 components were also compared separately in the
good and poor responder groups. Subsequently, changes
in a further 10 DMPs between baseline and 4 weeks were
correlated with changes in individual DAS components
either at the two specific time points or in the separate
responder groups where the change was seen between
baseline and 4 weeks (P< 1106): three DMPs were
associated with change in TJC, three other DMPs were
associated with change in SJC, and a further four DMPs
were associated with change in CRP (Tables 2 and 3).
Replication of epigenome-wide findings using
pyrosequencing
Significant differential methylation was replicated at four
of the 12 CpGs (cg26764200, cg23700278, cg27427581,
cg04334751), for the same trait and with the same direc-
tion of effect in the independent data set of a further 100
samples from the RAMS study (P< 0.01) (Table 4). The
results of Table 4 show that small decreases in the SJC
or CRP correlated with modest increases in methylation.
While these changes seem small, considering, for ex-
ample, cg23700278, where every 0.20 decrease in SJC
correlated with a 0.17% increase in methylation, an im-
provement of SJC by 5 would correspond to 4.25% in-
crease in methylation at 4 weeks.
TABLE 3 Top 10 DMPs after 4 weeks of treatment associated with response
CpG site Parameter
Change in DAS28
component P-value
Nearest
gene
Relation to
nearest gene
cg13793478 TJC at 4 weeks +0.07 9.78  108 FOXD4 
cg19357849 TJC at 4 weeks +0.05 7.73  107 ELAVL1 TSS1500
cg06201514 TJC in good responders +0.06 2.90  107 MYT1L Gene body
cg23700278 SJC in good responders 0.13 1.97  1010 ADRA2C 
cg27427581 SJC in good responders 0.10 6.45  109 GATA3 
cg16682276 SJC in poor responders +0.03 1.25  106 GNMT TSS1500
CRP at baseline 0.06 5.01  108
cg04334751 CRP at 4 weeks 0.16 1.31  1012 MIR182 
CRP in poor responders 0.32 2.80  1014
cg08799865 CRP at 4 weeks 0.19 1.17  1013 NT5C2 TSS200
cg26764200 CRP in good responders 0.23 8.71  1010 SNORD84; BAT1 TSS1500
CRP at baseline 0.06 3.77  1011
cg04115006 CRP at 4 weeks 0.14 1.84  1011 C14orf180 30UTR
CRP at 4 weeks in poor responders 0.34 3.97  1020
Top 10 CpG sites where every 1% increase in methylation corresponded to change in DAS28 component. Where time point
features as a parameter, the changes in methylation and in DAS28 component score at 6 months were found at that time
point. Where good or poor responder features as a parameter, the changes in DAS28 component correlated with changes in
methylation between time points in that responder group. TSS1500/200: 1500/200 base pairs upstream of the transcription
start site; 30UTR: 30-untranslated region; : not an annotated region.
TABLE 2 Two DMPs associated with treatment response after 4 weeks of MTX treatment
CpG site
Average methylation
in GR, %
Average methylation
in PR, % P-value
Nearest
gene
Relation
to gene
cg21040096 77.3 87.3 2.79  107 RPH3AL 50UTR
cg09894276 87.7 80.4 3.62  107 WDR27 Gene intron
Comparison of DNA methylation in samples taken after 4 weeks of treatment identified two differentially methylated positions
(DMPs) (P-value<106) that showed differences in methylation between good (GR) and poor (PR) responders. Response
status was based on EULAR response criteria using the composite DAS28 score calculated after 6 months of treatment. The
CpG sites were situated in the 50-untranslated region (50UTR) and intron of their respective nearest genes.
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Pathway analyses of replicated associations
In order to find evidence of involvement of these repli-
cated CpG sites in relevant biological pathways, the top
1000 CpG associations from the epigenome-wide analysis
for change in SJC in good responders, change in CRP in
baseline samples, and change in CRP in good responders
were analysed using the R package, missMethyl [18].
Significant interactions in biological pathways (P-value
<105) are reported in Tables 5 and 6 alongside P-
values that were adjusted for false discovery rate. The
most strongly associated pathways in both analyses
involved cell adhesion. There were no significant path-
ways reported for change in CRP in good responders.
MeQTL results
Methylation values for the replicated DMPs were investi-
gated for meQTLs using SNP data mapped to within 1
million bases around the replicated CpGs using the R
package matrixEQTL [21]. There was no evidence of
meQTLs at any of the replicated loci in this analysis.
Discussion
In this large EWAS of MTX response in RA, four DMPs that
predicted an improvement of SJC and CRP at 6 months
were identified in samples taken as early as 4 weeks from
RA patients commencing MTX for the first time who were
either extremely good or extremely poor responders by
6 months. These genetic loci are novel in the context of
RA and MTX response. Bioinformatics evidence suggests
that DNA methylation at these loci may modulate cellular
adhesion pathways. These biomarkers of response by
6 months were detectable as early as 4 weeks following
therapy initiation, potentially representing an advance on
current practice by providing an early indication of likely
future clinical response and allowing an escalation or
change in therapy to optimize efficacy.
In the discovery analysis, no significant changes in
methylation were seen between good and poor re-
sponders at baseline; however, two DMPs were identified
at 4 weeks. This would imply that changes in methylation
TABLE 5 Top gene ontology pathways associated with change in SJC in good responders
Gene Ontology term
Overall number of
genes in pathway
Number of input
genes in pathway P-value FDR adjusted
GO: 0007156 Homophilic cell adhesion
via plasma membrane
adhesion molecules
145 26 2.51  1015 5.04  1011
GO: 0098742 Cellcell adhesion via
plasma membrane
adhesion molecules
204 27 1.06  1013 1.07  109
GO: 0005509 Calcium ion binding 648 39 2.48 1010 1.66  106
GO: 0031224 Intrinsic component of
membrane
4936 111 5.29  106 0.025616
GO: 0007155 Cell adhesion 1350 50 8.17  106 0.025616
GO: 0016021 Integral component of
membrane
4823 108 8.51 106 0.025616
GO: 0022610 Biological adhesion 1355 50 8.92  106 0.025616
GO: 0098609 Cellcell adhesion 819 34 3.17  105 0.079549
GO: 0007268 Synaptic transmission 687 31 6.60  105 0.147292
GO: 0044425 Membrane part 5946 125 1.12  104 0.22557
The overall number of genes relates to the total number of genes in the pathway as annotated by Gene Ontology. The number
of input genes in the pathway relates to the genes captured by the CpG sites from the original epigenome-wide analyses.
FDR: false discovery rate.
TABLE 4 Four CpG associations were replicated in the pyrosequencing dataset
CpG " DAS component " methylation (%) Time point/response P-value Gene
cg23700278 0.20 (SJC) +0.17 GR 0.003 ADRA2C
cg27427581 0.06 (SJC) +0.23 GR 0.005 GATA3
cg04334751 0.15 (CRP) +0.15 BL 0.0002 MIR182
cg26764200 0.12 (CRP) +0.21 GR 0.005 SNORD84; BAT1
Two CpG sites were associated with an improvement of swollen joint count (SJC) at 6 months with increased methylation in
good responders (GR) by 4 weeks, and two additional CpG sites were associated with an improvement of CRP levels at
6 months with increased methylation in baseline (BL) samples, and in GR by 4 weeks.
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were due to the effect of MTX acting differently on patients
who by 6 months were in extreme responder groups. When
analysing the changes in DAS28 components with changes
in methylation, there was one CpG, cg04334751, for which
changes in methylation correlated with levels of CRP at
baseline. This was also replicated by pyrosequencing.
None of the four CpG sites mapped within CpG islands,
nor have these regions been associated with MTX metabol-
ism; however, these CpGs map close to genes that are of
biological interest in RA. For example, the cg27427581 DMP
maps close to the GATA3 gene region. GATA3 regulates
specific CD4+ T helper cell (Th2) differentiation and pro-
motes the expression of Th2 cytokine genes [22]. The
cg04334751 DMP maps close to the microRNA gene
MIR-182. There is emerging evidence that this microRNA
is regulated by a number of different transcription factors
that promote osteoclastogenesis, which ultimately leads to
osteolysis found in RA [23]. MIR-182 is involved in the TNF-
induced osteoclastogenesis programme, which is regulated
by transcription factors RBP-J, Foxo3 and Maml1 [23]. This
makes the RBP-JmiR-182Foxo3Maml1 pathway an at-
tractive candidate for therapeutic targeting [23], and MTX
may exert some of its actions via this pathway. Not only
does cg04334751 map to a region of potential biological
interest, it is also of clinical interest being the only biomarker
identified at the pre-treatment time point and was asso-
ciated with change in CRP. Alone, this DMP is not strong
enough to be a single biomarker of treatment response at
6 months; however, it may contribute to a panel of bio-
markers in the future that could be used to predict response.
Furthermore, while these loci are close to regions relevant to
RA pathogenesis, we cannot conclude that these CpG bio-
markers are specific to MTX response in RA. To ascertain
this, further investigation is required in patients who have
other diseases for which MTX is prescribed in low doses
such as psoriasis or systemic lupus erythematosus [24, 25].
While interesting CpG associations with improvement of
disease activity were identified in this study, integration
with genetic data did not find meQTLs at these loci.
Finding a more easily typed and stable biomarker such
as a SNP, which correlates with the DMP of interest,
would be more suitable for clinical use. However, these
findings in methylation data should be valued for further
exploration as a potential biomarker of response, particu-
larly as DNA methylation is still a more stable measure-
ment when compared with other biomarkers such as
transcriptomic signatures.
Strengths of the study include the selection of patients
for the first phase genome-wide EWAS; the power of the
study was optimized by analysing patients with extreme
response status, i.e. from the 2000 patients recruited to
the RAMS study, we selected patients who improved
most in DAS28 score by 6 months (good responders)
and those whose DAS28 improved least or indeed wor-
sened over 6 months. By taking into account the sugges-
tions by Tsai and Bell (2015), our study had over 80%
power to identify differences of 7% in methylation [17].
In addition, we adopted a quantitative approach in
which changes in methylation were compared with
changes in the individual components of the DAS28 at
6 months, in which replication of methylation changes
was found to correlate with changes in the more objective
components of the DAS28: CRP and SJC. A further
strength is that the RAMS cohort includes a representative
sample of patients commencing MTX in the UK.
Furthermore, samples were available at both the pre-
treatment time point and following 4 weeks of therapy,
allowing early response biomarkers to be identified. It
may be questioned whether the poor responders in a
given study are truly poor responders or whether in fact
they are non-adherent to the drug [4]. A further strength of
the current study is that adherence rate from self-report
diaries within the RAMS cohort has been found to exceed
80% at 6 months [26].
Nonetheless, some limitations should also be
recognized. It should be noted that RA is a relapsing
remitting disease and some changes in the DAS28 over
the 6 months may have arisen due to natural variation
rather than as a result of the MTX intervention as has
been reported for TNFi drugs recently [15]. The study
design does not allow separation of prognostic from ther-
anostic biomarkers as no control group was included, but
in terms of selecting treatments that will be effective, that
may not necessarily matter in the clinical setting [27].
However, this would have made it less likely to see a dif-
ference between good and poor responders; therefore,
TABLE 6 Top gene ontology pathways associated with change in CRP in baseline samples
Gene Ontology term
Overall number of
genes in pathway
Number of input
genes in pathway P-value FDR adjusted
GO: 0007156 Homophilic cell adhesion
via plasma membrane
adhesion molecules
145 17 2.08  106 0.041888
GO: 0098742 Cellcell adhesion via
plasma membrane ad-
hesion molecules
204 17 6.52  105 0.654594
The overall number of genes relates to the total number of genes in the pathway as annotated by Gene Ontology. The number
of input genes in the pathway relates to the genes captured by the CpG sites from the original epigenome-wide analyses.
FDR: false discovery rate.
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our reported differences in these responder groups are
encouraging.
While the study was adequately powered to detect
modest changes in methylation status, smaller differences
may have been missed. While small differences are less
likely to be clinically useful individually, they may be more
numerous and provide important added information in an
algorithm of response and may also provide mechanistic
insight into how MTX exerts its clinical benefit. Therefore,
the DMPs alone may not be sufficiently predictive of treat-
ment response to MTX to be clinically useful, especially
since the effects were modest; however, the effect was
replicated, the patients are real-world and no effect at the
same positions was reported in the previous TNFi EWAS
study [8]. To conduct an investigation that can be more
easily translatable to clinic we chose to test our hypotheses
in whole blood samples from RA patients. Since whole
blood is a heterogeneous population of blood cells, each
with its own distinct methylome, it is important to take into
account these differences in analyses. We used the
Houseman method [14] to estimate cellular composition
based on a reference dataset of the distribution of methy-
lation in these cell types and found no significant differences
between the good and poor responders in our study; how-
ever, we may have missed more informative DNA methyla-
tion biomarkers present in specific cell subsets.
In conclusion, we have found and replicated associ-
ations of four DMPs that are identified by 4 weeks of
MTX initiation, which correlate with clinical response at
6 months. The findings in the current study are promising
and appear to identify methylation patterns that are pre-
dictive of improvement of SJC and CRP, which are the
more objective components of the DAS28 disease activity
score and correlate better with ultrasound synovitis
scores. While they are insufficiently predictive alone to
be clinically useful, they could be incorporated into algo-
rithms including clinical data and other genetic, epigen-
etic, genomic and proteomic biomarkers, to provide a
more robust predictor of response in RA and use of pre-
cision medicine approaches to guide treatment decisions.
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